Director Michael Stansky Buys $1.53M in TriSalus Life Sciences Stock
Summary
Director Michael P. Stansky purchased $1.53 million worth of TriSalus Life Sciences common stock in open-market transactions, signaling strong confidence in the company's valuation after recent mixed earnings.
Key Events
-
Director's Substantial Purchase
Director Michael P. Stansky acquired 610,000 shares of TriSalus Life Sciences common stock for $1,525,000 in open-market transactions on May 15, 2026.
-
Open-Market Conviction
This is an open-market purchase (Code P), indicating a direct investment of personal capital and strong belief in the company's future prospects.
-
Price Point and Timing
The shares were purchased at a weighted average price of $2.50, which is below the company's current stock price of $2.97 and significantly lower than the $4.10 price of the public offering in February 2026, where Stansky also purchased shares. This suggests confidence at a lower valuation.
-
Adds to Insider Accumulation
This purchase contributes to a pattern of insider accumulation, with over $1.67 million in net open-market buys by insiders over the last 90 days.
Analysis
Director Michael Stansky's substantial open-market purchase of $1.53 million in TriSalus Life Sciences stock signals strong conviction in the company's value, particularly following recent mixed Q1 2026 results and a public offering in February. This purchase, made at $2.50 per share, is notably below the $4.10 price of the February offering and Stansky's own previous purchase, suggesting he sees significant value at current levels. It also reinforces a broader trend of insider accumulation over the past 90 days.
At the time of this filing, TLSI was trading at $2.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $186.1M. The 52-week trading range was $2.20 to $7.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.